Cargando…

A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim

Proteins are an increasingly important class of drugs used as therapeutic as well as diagnostic agents. A generic physiologically based pharmacokinetic (PBPK) model was developed in order to represent at whole body level the fundamental mechanisms driving the distribution and clearance of large mole...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niederalt, Christoph, Kuepfer, Lars, Solodenko, Juri, Eissing, Thomas, Siegmund, Hans-Ulrich, Block, Michael, Willmann, Stefan, Lippert, Jörg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845054/ https://www.ncbi.nlm.nih.gov/pubmed/29234936 http://dx.doi.org/10.1007/s10928-017-9559-4

Ejemplares similares

Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim
por: Basu, Sumit, et al.
Publicado: (2020)

A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interactions
por: Frechen, Sebastian, et al.
Publicado: (2021)

A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks
por: Eissing, Thomas, et al.
Publicado: (2011)

Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
por: Kuepfer, L, et al.
Publicado: (2016)

A Generic Integrated Physiologically based Whole-body Model of the Glucose-Insulin-Glucagon Regulatory System
por: Schaller, S, et al.
Publicado: (2013)

Predictive Performance of Physiology‐Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small‐Molecule Compounds in Children
por: Ince, Ibrahim, et al.
Publicado: (2021)

Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals
por: Schlender, Jan-Frederik, et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance
por: Dickschen, Kristin, et al.
Publicado: (2012)

Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin
por: Willmann, Stefan, et al.
Publicado: (2019)

Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models
por: Vossen, Michaela, et al.
Publicado: (2007)

A Detailed Physiologically Based Model to Simulate the Pharmacokinetics and Hormonal Pharmacodynamics of Enalapril on the Circulating Endocrine Renin-Angiotensin-Aldosterone System
por: Claassen, Karina, et al.
Publicado: (2013)

Development of a Physiologically Based Computational Kidney Model to Describe the Renal Excretion of Hydrophilic Agents in Rats
por: Niederalt, Christoph, et al.
Publicado: (2013)

A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life
por: Schlender, Jan-Frederik, et al.
Publicado: (2018)

Applied Concepts in PBPK Modeling: How to Extend an Open Systems Pharmacology Model to the Special Population of Pregnant Women
por: Dallmann, André, et al.
Publicado: (2018)

Towards whole-body systems physiology
por: Kuepfer, Lars
Publicado: (2010)

Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban
por: Willmann, Stefan, et al.
Publicado: (2013)

Physiologically Based Simulations of Deuterated Glucose for Quantifying Cell Turnover in Humans
por: Lahoz-Beneytez, Julio, et al.
Publicado: (2017)

First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development
por: Strougo, Ashley, et al.
Publicado: (2012)

Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling
por: Dickschen, Kristin, et al.
Publicado: (2014)

Integrating Cellular Metabolism into a Multiscale Whole-Body Model
por: Krauss, Markus, et al.
Publicado: (2012)

Data‐driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessment
por: Fendt, Rebekka, et al.
Publicado: (2021)

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study
por: Willmann, Stefan, et al.
Publicado: (2018)

Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban—an oral, direct Factor Xa inhibitor
por: Burghaus, Rolf, et al.
Publicado: (2014)

A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy
por: Cordes, Henrik, et al.
Publicado: (2016)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions
por: Willmann, Stefan, et al.
Publicado: (2021)

Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification
por: Krauss, Markus, et al.
Publicado: (2013)

Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations
por: Krauss, Markus, et al.
Publicado: (2015)

Spatio-Temporal Simulation of First Pass Drug Perfusion in the Liver
por: Schwen, Lars Ole, et al.
Publicado: (2014)

Physiologically-based pharmacokinetic modelling and dosing evaluation of gentamicin in neonates using PhysPK
por: Zazo, Hinojal, et al.
Publicado: (2022)

Quantitative systems pharmacology of interferon alpha administration: A multi-scale approach
por: Kalra, Priyata, et al.
Publicado: (2019)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation
por: Burghaus, Rolf, et al.
Publicado: (2011)

Interchangeability of Generics—Experiences and Outlook Toward Pharmacokinetics Variability and Generic‐Generic Substitution
por: Yu, Yang, et al.
Publicado: (2018)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

SimCT: a generic tool to visualize ontology-based relationships for biological objects
por: Herrmann, Carl, et al.
Publicado: (2009)

1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
por: Bradley, John, et al.
Publicado: (2018)

Physiologically‐based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate
por: Farhan, Nashid, et al.
Publicado: (2021)

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
por: Wendl, Thomas, et al.
Publicado: (2021)

Interchangeability of Generic Drugs: A Nonparametric Pharmacokinetic Model of Gabapentin Generic Drugs
por: Glerum, Pieter J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qijfmvgv5rl57u5ss1ej0j8gc9